Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
Authors:
- Dinesh KhannaDKDinesh Khanna
- Vivek NagarajaVNVivek Nagaraja
- Chi-Hong TsengCTChi-Hong Tseng
- Fereidoun AbtinFAFereidoun Abtin
- Robert SuhRSRobert Suh
- Grace KimGKGrace Kim
- Athol WellsAWAthol Wells
- Daniel E. FurstDFDaniel E. Furst
- Philip J. ClementsPCPhilip J. Clements
- Michael D. RothMRMichael D. Roth
- Donald P. TashkinDTDonald P. Tashkin
- Jonathan GoldinJGJonathan Goldin
Open Access
- 23 December 2015
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 17 (1) , 372
Abstract
The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in 25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users.Keywords
Funding Information
- NIH/NIAMS (5K24AR063120)
This publication has 36 references indexed in Scilit:
- Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and NintedanibNew England Journal of Medicine, 2015
- Old medications and new targeted therapies in systemic sclerosisRheumatology, 2014
- Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important DifferenceAmerican Journal of Respiratory and Critical Care Medicine, 2011
- A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.2010
- Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study DesignCurrent Rheumatology Reviews, 2010
- Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.2007
- Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung studyArthritis & Rheumatism, 2007
- The Lung in Systemic SclerosisJCR: Journal of Clinical Rheumatology, 2005
- The Predictive Value of Appearances on Thin-section Computed Tomography in Fibrosing AlveolitisAmerican Review of Respiratory Disease, 1993
- High resolution computed tomography as a predictor of lung histology in systemic sclerosis.Thorax, 1992